在食道状细胞癌中,SIRT1促进化学辐射疗法抵抗
Hiroki Morishita1, Ryota Otsuka1, Kentaro Murakami1
1Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Oncology
|July 7, 2024
概括
高SIRT1蛋白表达预测食道状细胞癌 (ESCC) 中化学放射治疗 (CRT) 的反应不佳. 抑制SIRT1可以提高对CRT的敏感性,这表明SIRT1是ESCC治疗的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 在食道状细胞癌 (ESCC) 中预测化疗辐射疗法 (CRT) 反应仍然是一个挑战.
- 赛尔图因1 (SIRT1) 涉及ESCC瘤促进,但其在CRT敏感性中的作用尚不清楚.
研究的目的:
- 研究ESCC中SIRT1表达和CRT灵敏度之间的关系.
- 评估SIRT1淘汰对ESCC细胞系中CRT敏感性的影响.
主要方法:
- 在接受CRT的73名ESCC患者的治疗前活检中通过免疫染评估SIRT1表达.
- 利用小干扰RNA减少ESCC细胞系中SIRT1的表达 (TE5,TE10).
- 暴露于不同剂量的西斯和X射线辐射的细胞.
主要成果:
- 高SIRT1表达与对CRT的抵抗有显著的相关性.
- 多变量分析发现高SIRT1是CRT反应不良的独立预测因子.
- 在细胞系中SIRT1的敲击降低了活力,并增加了对西斯和辐射的敏感性.
结论:
- 在ESCC中,SIRT1显示出作为CRT响应预测生物标志物的潜力.
- 对SIRT1的转录性失活增强了ESCC对CRT的敏感性.
- 向SIRT1可能会提高ESCC治疗中的CRT疗效.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


